Gregory Parker

Gregory Parker has worked in the biotechnology industry since 2008. From 2008 to 2012, they were a Principal Scientist at RGo Bioscience, where they led the company's efforts in characterizing the biophysical properties of peptide/siRNA nanoparticle formulations for use as novel RNA interference (RNAi) therapeutics. Gregory also screened a library of siRNA-binding compounds to establish structure-function relationships, and developed methodologies for formulation scale-up and purification. From 2012 to 2013, they were a Manager of Production and Quality Control, and a Scientist at Stemgent. At Stemgent, they optimized and produced large scale in vitro transcription reactions of mRNAs used in cellular reprogramming and directed differentiation protocols, and derived induced pluripotent stem cell (iPSC) lines via mRNA reprogramming. From 2013 to 2019, they were a Senior Scientist, Research Scientist II, and Project Leader at eFFECTOR Therapeutics, Inc. At eFFECTOR, they facilitated advancing two programs from early discovery to the clinic, performed mechanism of action (MOA) studies, collaborated with DMPK and in vivo teams to define PK/PD/efficacy relationships for top candidate compounds, designed, optimized, and implemented screening assay cascades for two distinct oncology drug discovery programs, produced experimentally robust screening data, and managed multiple external CRO relationships. Since 2019, they have been a Director and Associate Director of Biology at Plexium.

Gregory Parker earned a B.S. in Chemistry from Black Hills State University between 1994 and 1998. Gregory then pursued a Ph.D. in Biochemistry from the University of Utah, which they completed in 2008.